Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALLENA PHARMACEUTICALS, INC.

(ALNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALLENA PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

09/29/2021 | 08:44am EST

Item 8.01 Other Information

On September 29, 2021, Allena Pharmaceuticals, Inc. issued a press release to report that it has dosed the first patient in a second Phase 2a trial of ALLN-346, a novel, orally-administered, urate-degrading enzyme in development for the treatment of gout in patients with chronic kidney disease. A copy of the press release is filed herewith as Exhibit 99.1 to this Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release of Allena Pharmaceuticals, Inc., dated September 29,
            2021.

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ALLENA PHARMACEUTICALS, INC.
11/16ALLENA PHARMACEUTICALS : Corporate Presentation November 2021
PU
11/15Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
GL
11/15Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference
GL
11/12ALLENA PHARMACEUTICALS : Amendment to Annual Report (Form 10-K/A)
PU
11/12ALLENA PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/10Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporat..
PU
11/10Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporat..
AQ
11/10Allena Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/03Allena Pharmaceuticals Receives FDA Fast-Track Designation for Hyperuricemia Treatment ..
MT
11/03Allena Pharmaceuticals Gets Fast Track Designation for Kidney Disease Treatment
DJ
More news
Analyst Recommendations on ALLENA PHARMACEUTICALS, INC.
More recommendations